<DOC>
	<DOCNO>NCT01003184</DOCNO>
	<brief_summary>The purpose study compare effect exenatide weekly ( QW ) insulin detemir respect glycemic control , body weight , lipid , safety , tolerability , patient report outcome .</brief_summary>
	<brief_title>Efficacy Once-Weekly Exenatide Versus Once Twice Daily Insulin Detemir Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Have suboptimal glycaemic control evidence HbA1c 7.1 % 10.0 % , inclusive Have body mass index ( BMI ) 25 kg/m2 45 kg/m2 , inclusive Are receive metformin stable dose ( consistent country specific requirement ) minimum 1000mg least 3 month prior start start OR receive metformin minimum dose ( consistent country specific requirement ) 1000mg sulphonylurea ( separate medication fix dose combination ) stable dos 3 month prior study start Have contraindication OAD use Have know allergy hypersensitivity insulin detemir , exenatide excipients contain agent Have treat within 4 week screen systemic glucocorticoid therapy oral , intravenous ( IV ) intramuscular ( IM ) route , regularly treat potent , inhale intranasal steroid know high rate systemic absorption . Exceptions criterion include patient receive glucocorticoid therapy corticotropic hypopituitary deficiency ( e.g . Addison disease ) Have treat drug promote weight loss , within 3 month screen Have treat longer 2 week follow excluded medication within 3 month prior screen : insulin , alphaglucosidase , ByettaÂ® ( exenatide BID formulation ) , thiazolidinediones ( TZD ) , dipeptidyl peptidase ( DPP ) 4 inhibitor Have previously complete withdrawn study study investigate exenatide QW Have receive treatment within last 30 day drug receive regulatory approval indication time study entry Are currently enrol , discontinue within last 30 day , clinical trial involve offlabel use investigational drug device ( study drug/device use study ) , concurrently enrol type medical research judge scientifically medically compatible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide weekly</keyword>
	<keyword>Byetta</keyword>
	<keyword>insulin detemir</keyword>
	<keyword>Levemir</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>